Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind.

Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million doses intended to supply the U.S. market starting in the third quarter of 2020. The companies said they are in discussions to secure fill-finish capacity for continued production of hundreds of millions of additional doses. Somerset, N.J.-based Catalent will also provide clinical supply services from its facilities in Philadelphia, including packaging and labeling, as well as storage and distribution to support Moderna’s Phase 3 clinical study for this candidate.

Get the full story on our sister site, Pharmaceutical Processing World.